Alzamend Neuro, Inc. (ALZN)

Alzamend Neuro is a clinical-stage biopharmaceutical company dedicated to developing therapeutic candidates for neurodegenerative and psychiatric disorders, particularly Alzheimer’s disease, major depressive disorder, bipolar disorder, and post-traumatic stress disorder. Founded in 2016 and based in Atlanta, Georgia, the company operates on two distinct platforms: one leveraging ionic cocrystal technology to deliver therapeutic compounds, and another employing cell-based immunotherapy approaches. Both of its lead product candidates are licensed exclusively from the University of South Florida Research Foundation under royalty-bearing agreements.

The company’s pipeline centers on two primary candidates. AL001 represents Alzamend’s ionic cocrystal technology—a patented formulation combining lithium with proline and salicylate that aims to deliver lithium’s therapeutic benefits while potentially mitigating side effects. The compound has advanced through Phase II studies with results suggesting an acceptable safety profile and therapeutic signal in certain neuropsychiatric conditions. ALZN002, the company’s cell-based therapeutic vaccine candidate, targets Alzheimer’s disease by attempting to restore immune function against beta-amyloid pathology; the FDA granted a Study May Proceed letter in late 2022, and clinical trials began in early 2023.

As an early-stage biotech with no approved products, Alzamend remains dependent on capital deployment and clinical progress to validate its therapeutic hypotheses. The company’s reliance on university-licensed intellectual property and the length of the drug development pipeline mean that meaningful commercial returns remain years away. Investors monitoring Alzamend track clinical trial readouts and regulatory milestones as primary catalysts, while the company’s cost structure and cash runway remain operational constraints common to clinical-stage peers.